Research demonstrates interleukin 17's role in autoimmune thyroid diseases, suggesting it as a promising treatment target.
IL-23/IL-17 axis and Th17/Treg imbalance are critical checkpoints in the AITD pathogenesis. IL-17 represents a promising, yet still experimental immunotherapeutic target, warranting rigorous clinical investigation.
No takes yet. Share an insight, caveat, or question.
Huihong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: